MX2017009482A - Formulación farmacéutica. - Google Patents

Formulación farmacéutica.

Info

Publication number
MX2017009482A
MX2017009482A MX2017009482A MX2017009482A MX2017009482A MX 2017009482 A MX2017009482 A MX 2017009482A MX 2017009482 A MX2017009482 A MX 2017009482A MX 2017009482 A MX2017009482 A MX 2017009482A MX 2017009482 A MX2017009482 A MX 2017009482A
Authority
MX
Mexico
Prior art keywords
injection
pharmaceutical formulation
pharmaceutical compositions
corticosteroid
intra
Prior art date
Application number
MX2017009482A
Other languages
English (en)
Other versions
MX386732B (es
Inventor
G Shah Mahendra
Original Assignee
Semnur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semnur Pharmaceuticals Inc filed Critical Semnur Pharmaceuticals Inc
Publication of MX2017009482A publication Critical patent/MX2017009482A/es
Publication of MX386732B publication Critical patent/MX386732B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describen composiciones farmacéuticas acuosas que proporcionan administración liberada sostenida de compuestos corticosteroides. La composición farmacéutica comprende un corticosteroide soluble y al menos un agente potenciador de la viscosidad. También se proporcionan métodos para utilizar las composiciones farmacéuticas en una inyección epidural, una inyección intraarticular o una inyección intralesional.
MX2017009482A 2015-01-21 2016-01-20 Composición farmacéutica de corticosteroide soluble. MX386732B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562106045P 2015-01-21 2015-01-21
PCT/US2016/014165 WO2016118649A1 (en) 2015-01-21 2016-01-20 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
MX2017009482A true MX2017009482A (es) 2017-11-15
MX386732B MX386732B (es) 2025-03-19

Family

ID=55405453

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009482A MX386732B (es) 2015-01-21 2016-01-20 Composición farmacéutica de corticosteroide soluble.
MX2021012029A MX2021012029A (es) 2015-01-21 2017-07-20 Composicion farmaceutica de corticosteroide soluble.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012029A MX2021012029A (es) 2015-01-21 2017-07-20 Composicion farmaceutica de corticosteroide soluble.

Country Status (13)

Country Link
US (4) US10500284B2 (es)
EP (2) EP3247329B3 (es)
JP (4) JP6829201B2 (es)
KR (2) KR102600792B1 (es)
CN (2) CN107205926B (es)
AU (1) AU2016209332B2 (es)
BR (1) BR112017015452B1 (es)
CA (1) CA2974657C (es)
ES (1) ES2877371T7 (es)
IL (1) IL253570B (es)
MX (2) MX386732B (es)
TW (3) TWI845973B (es)
WO (1) WO2016118649A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ709620A (en) 2013-01-23 2020-07-31 Semnur Pharmaceuticals Inc Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
TWI845973B (zh) 2015-01-21 2024-06-21 美商桑紐爾製藥公司 醫藥配方
CN107635604A (zh) 2015-06-02 2018-01-26 英特拉维特私人有限公司 含有预组装配药筒的药物输送装置
WO2020014118A1 (en) 2018-07-09 2020-01-16 Taiwan Liposome Co., Ltd. Methods to reduce complications of intra-articular steroid
IT201800010415A1 (it) * 2018-11-19 2020-05-19 Innate S R L Composizione iniettabile comprendente acido ialuronico e trealosio e uso della detta composizione.
CN112870155B (zh) * 2021-03-08 2023-06-30 上海昱聚科技有限公司 缓释地塞米松药物的凝胶注射剂及其制备方法和应用
US12285541B2 (en) * 2023-01-26 2025-04-29 Insignia Pharmaceuticals, Llc Pharmaceutical compositions for treating osteoarthritis
WO2025219919A1 (en) * 2024-04-19 2025-10-23 Beam Medical Inc. Anesthetic pharmaceutical compositions, kits and uses thereof for slow release of an anesthetic agent and concurrent medical imaging of its distribution

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25251A (en) 1965-07-20 1969-11-12 Merck & Co Inc Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation
US3962430A (en) 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
IL80298A (en) * 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
FI105075B (fi) 1996-01-10 2000-06-15 Suprakort Oy Kombinaatioinjektiovalmisteen käyttö
IT1288290B1 (it) 1996-06-21 1998-09-11 Fidia Spa In Amministrazione S Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
JPH11279065A (ja) * 1998-03-25 1999-10-12 Shiseido Co Ltd 局所投与炎症治療剤
US6921532B1 (en) 2000-06-22 2005-07-26 Spinal Restoration, Inc. Biological Bioadhesive composition and methods of preparation and use
US6747090B2 (en) 2001-07-16 2004-06-08 Pharmacia Groningen Bv Compositions capable of forming hydrogels in the eye
US20040006052A1 (en) 2002-04-15 2004-01-08 Gudas Charles J. Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use
CN101094690A (zh) * 2003-11-12 2007-12-26 阿勒根公司 用于治疗眼后节的组合物及方法
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050186229A1 (en) * 2004-02-24 2005-08-25 Emmett Clemente Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate
JP2007001926A (ja) 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
JP4969812B2 (ja) 2005-07-22 2012-07-04 久光製薬株式会社 ハイドロゲル組成物
US20070099882A1 (en) 2005-10-27 2007-05-03 Gurney Harry C Methods and compositions for prolonged alleviation of articular joint pain
WO2007070547A2 (en) * 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US20070141160A1 (en) 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
CN100534434C (zh) 2006-05-15 2009-09-02 西安力邦制药有限公司 透明质酸钠地塞米松脂肪乳制剂及其应用
EP2089035A1 (en) * 2006-11-02 2009-08-19 Riolan Technologies, Inc. Method for treating blepharitis
US20080317805A1 (en) 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9421356B2 (en) 2007-08-28 2016-08-23 Teikoku Pharma Usa, Inc. Transdermal methods and systems for the delivery of corticosteroid compounds
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20090143807A1 (en) 2007-12-03 2009-06-04 Vertos Medical, Inc., A Delaware Corporation Percutaneous Devices for Separating Tissue, Kits and Methods of Using the Same
EP2234619A4 (en) 2008-04-18 2010-10-27 Medtronic Inc METHOD AND COMPOSITIONS FOR TREATMENT OF BELT WASTE TREATMENTS
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
CN101683532A (zh) * 2008-09-25 2010-03-31 武汉诺安药业有限公司 含玻璃酸或其盐的眼用复方药物制剂
WO2010054356A1 (en) 2008-11-10 2010-05-14 Nitric Biotherapeutics, Inc. Pharmaceutical formulations for iontophoretic delivery of a corticosteroid
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
RU2459615C1 (ru) * 2011-03-05 2012-08-27 Илья Александрович Марков Глазные капли для лечения болезни сухого глаза
WO2013085769A1 (en) 2011-12-06 2013-06-13 Alcon Research, Ltd. Cellulosic gel composition with improved viscosity stability
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
NZ709620A (en) 2013-01-23 2020-07-31 Semnur Pharmaceuticals Inc Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
TWI845973B (zh) 2015-01-21 2024-06-21 美商桑紐爾製藥公司 醫藥配方

Also Published As

Publication number Publication date
WO2016118649A1 (en) 2016-07-28
TWI674899B (zh) 2019-10-21
CN107205926B (zh) 2021-03-05
KR20230157534A (ko) 2023-11-16
US10500284B2 (en) 2019-12-10
ES2877371T3 (es) 2021-11-16
CA2974657C (en) 2024-02-20
US20210386859A1 (en) 2021-12-16
HK1243932A1 (zh) 2018-07-27
EP3247329B3 (en) 2022-02-09
AU2016209332B2 (en) 2020-10-22
US20180185494A1 (en) 2018-07-05
TW202245791A (zh) 2022-12-01
JP2020073576A (ja) 2020-05-14
MX2021012029A (es) 2021-10-26
EP3925597A1 (en) 2021-12-22
AU2016209332A1 (en) 2017-09-07
CA2974657A1 (en) 2016-07-28
CN107205926A (zh) 2017-09-26
CN112957320A (zh) 2021-06-15
KR102824858B1 (ko) 2025-06-26
US12285485B2 (en) 2025-04-29
US20200197523A1 (en) 2020-06-25
JP2021143209A (ja) 2021-09-24
ES2877371T7 (es) 2022-05-24
TW202005652A (zh) 2020-02-01
JP2021183649A (ja) 2021-12-02
EP3247329B1 (en) 2021-05-19
BR112017015452A2 (pt) 2018-01-23
IL253570A0 (en) 2017-09-28
US10117938B2 (en) 2018-11-06
TWI772659B (zh) 2022-08-01
JP7269992B2 (ja) 2023-05-09
MX386732B (es) 2025-03-19
US20180008714A1 (en) 2018-01-11
JP7065129B2 (ja) 2022-05-11
US11020485B2 (en) 2021-06-01
HK1245653A1 (zh) 2018-08-31
IL253570B (en) 2020-08-31
JP6829201B2 (ja) 2021-02-10
TWI845973B (zh) 2024-06-21
EP3247329A1 (en) 2017-11-29
KR102600792B1 (ko) 2023-11-10
TW201630609A (zh) 2016-09-01
KR20170103974A (ko) 2017-09-13
BR112017015452B1 (pt) 2022-11-08
JP2018502872A (ja) 2018-02-01

Similar Documents

Publication Publication Date Title
MX2017009482A (es) Formulación farmacéutica.
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
NZ709620A (en) Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX2016001480A (es) Formulacion de inhibidores de syk.
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
AR101236A1 (es) Composiciones para el cuidado oral
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2018001590A1 (es) Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina.
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
MX2019005925A (es) Composiciones de alergenos liquidas y metodos para la preparacion de las mismas.
BR112021022194A2 (pt) Formulações líquidas para dosagem oral de metilnaltrexona
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
CL2018002200A1 (es) Administración combinada de un agente de penetración y un compuesto de azufre que contiene compuesto para las plantas.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
MX2019000717A (es) Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos.
CL2017001077A1 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral